Summit Therapeu ADR SMMT

$15.47 -0.08 (-0.51%)

Valuation

Market cap
12,435,740,000
Revenue TTM
$0
Net income TTM
$-1,079,590,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
3,209,200
Avg volume
6,668,250
Day's range
$15.07 – $15.55
Shares out
799,726,000
Stochastic %K
41%
Beta
-1.51
Analysts
Strong Sell
Price target
$29.14

Price

Company profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company...

Show more

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
305 203 2034
Website
https://www.smmttx.com
Address
601 Brickell Key Drive, Suite 1000, Miami, United States

Latest news

Stocktwits

Merlintrader Oct 24, 6:21 AM
$SMMT Oct 23, 2026: Summit and Lunit signed a research agreement to apply Lunit SCOPE IO, an AI pathology platform, to H&E whole-slide images in ivonescimab programs, aiming at biomarker discovery and patient selection. No clinical data announced. Summit Therapeutics ($SMMT): What Does the FDA Need to See by November 14? https://www.merlintrader.com/summit-therapeutics-stock-hub/ Technical picture: price 15.47 dollars, slightly below its 20, 50 and 200-day averages (-5%, -2%, -5%), RSI 45 (neutral). Chart: Finviz (affiliate) https://www.merlintrader.com/go/fv/SMMT Not investment advice.
0 replies
flychicken1991 Oct 24, 1:31 AM
$SMMT Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development. Impact: Positive (81%). could receive slight upward valuation support from greater confidence in ivonescimab development, but the agreement provides no demonstrated improvement in efficacy, revenue potential or approval timing. Source and what to watch next: https://nimpact.tech/newsimpact/news/1817066c514fb184/smmt-lunit-and-summit-therapeutics-announce-agreement-to-apply-ai-powere?utm_source=stocktwits&utm_medium=story_url
1 replies
BiotechSwings Oct 23, 11:59 PM
22 days. $SMMT goes to the FDA Nov 14 on ivonescimab plus chemo after a third gen EGFR TKI HARMONi hit a 0.52 hazard ratio on progression free survival and the survival number keeps improving with every follow up cut. stock sits at 15.47 with AstraZeneca paying 18.36 a share for its seat. I don't see 15 as the verdict here, imo the discount is doing the worrying, not the data
0 replies
ChillPill1972 Oct 23, 10:51 PM
$SMMT 10 posters this weekend! 🙏 https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Data-Sets-across-Multiple-Tumor-Types-to-Be-Featured-at-ESMO-2026/default.aspx
0 replies
QuantInsider Oct 23, 9:42 PM
$SMMT is in a holding pattern, gearing up for the ivonescimab data drop at ESMO on October 25 Spotted 1,802 Nov 20 $25 calls on InsiderFinance Deep OTM sweeps hint at speculative upside but don't ignore the downside plays A big 1,577-contract Oct 30 $12 put sweep shows traders hedging bets Feels like a two-sided event play rather than a clear trend Keep an eye on those gaps
2 replies
AlwaysABullNeverABear Oct 23, 8:58 PM
$SMMT
0 replies
AlertsAndNews Oct 23, 8:39 PM
$SMMT headline here Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
0 replies
Teluride Oct 23, 8:19 PM
$SMMT Hey dudes! The closing bell has rung, and we’re officially in after-hours trading! The next three weeks could be one wild ride, with some monster waves headed our way. Bulls and bears, better buckle up! And if you mothers can’t stand the heat, you better get out of the kitchen! This ride ain’t for the faint of heart!
0 replies